Search
Vanda Pharmaceuticals Inc
VNDAAdd to Watchlist
5.130USD
+0.020+0.39%
Close 09-18 16:00（ET）
309.23MMarket Cap
LossP/E TTM
Vanda Pharmaceuticals Inc (VNDA) Revenue Performance
Updated: Jun 30, 2026Last year, Vanda Pharmaceuticals Inc generated 117.30M USD for its biggest-performing segment, Fanapt. The United States made the largest contribution, accounting for 216.10M USD last year.
By Business
Revenue
Proportion
Annual
Annual
Quarterly
Fanapt
Hetlioz
PONVORY
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Fanapt
117.30M(54.28%)
94.30M(47.44%)
90.87M(47.17%)
94.73M(37.24%)
95.15M(35.41%)
87.48M(35.25%)
84.21M(37.07%)
77.28M(40.02%)
Hetlioz
71.43M(33.05%)
76.67M(38.57%)
100.17M(52.00%)
159.66M(62.76%)
173.54M(64.59%)
160.69M(64.75%)
142.98M(62.93%)
115.83M(59.98%)
PONVORY
27.37M(12.67%)
27.80M(13.99%)
1.60M(0.83%)
--(--)
--(--)
--(--)
--(--)
--(--)
By Region
Revenue
Proportion
Annual
Annual
Quarterly
United States
FY2025
FY2024
United States
216.10M(100.00%)
198.77M(100.00%)